Literature DB >> 8044263

Lack of association of glucocorticoid therapy and retinopathy of prematurity.

K Wright1, S P Wright.   

Abstract

OBJECTIVE: To determine if glucocorticoid therapy alters the severity of retinopathy of prematurity (ROP).
DESIGN: Retrospective survey.
SETTING: Tertiary intensive care nursery. PATIENTS: One hundred forty-seven surviving infants with birth weight of 1.25 kg or less born July 1990 through January 1993. OUTCOME MEASURES: Maximum stage of retinopathy and the need for cryosurgery.
RESULTS: Using logistic regression, neither corticosteroid exposure nor total corticosteroid dose was associated with either ROP greater than stage 2 or cryosurgery. The significant predictors of ROP greater than stage 2 were birth weight and the duration of supplemental oxygen therapy. The only significant risk factor for cryosurgery was gestational age.
CONCLUSIONS: No association between corticosteroid therapy and the severity of ROP was found after controlling for traditional risk factors such as birth weight, gestational age, and duration of supplemental oxygen therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044263     DOI: 10.1001/archpedi.1994.02170080078015

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  3 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

Review 2.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

3.  Retinopathy of prematurity and risk factors: a prospective cohort study.

Authors:  Padmani Karna; Jyotsna Muttineni; Linda Angell; Wilfried Karmaus
Journal:  BMC Pediatr       Date:  2005-06-28       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.